OBJECTIVE	To compare efficacy , resistance development , and safety between rilpivirine and efavirenz in treatment-naive , HIV-1-infected adults with baseline viral load 100,000 copies/ml or less in the pooled 48-week dataset of the ECHO ( Efficacy Comparison in treatment-naive HIV-infected subjects Of TMC278 and EFV ) and THRIVE ( TMC278 against HIV , in a once-daily RegImen Vs. Efavirenz ) trials .\